alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT
32.2





CERTIFICATION
OF CHIEF FINANCIAL OFFICER


PURSUANT
TO


18 U.S.C.
SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





I, Judy
Bruner, Chief Financial Officer of SanDisk Corporation, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that the annual report on Form 10-K of SanDisk Corporation for the
year ended December 28, 2008 (the “Report”) fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934
and that the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of SanDisk
Corporation.





By:   /s/ Judy Bruner


Judy Bruner


Executive Vice President,
Administration and Chief Financial Officer


(Principal Financial and Accounting
Officer)





February 25,
2009





A signed
original of this written statement required by Section 906 has been provided to
SanDisk Corporation and will be retained by SanDisk Corporation and furnished to
the Securities and Exchange Commission or its staff upon request.
#### UNITED STATES of America, Plaintiff—Appellee, v. Orlando WALLACE, Defendant—Appellant.

No. 08-7101.

United States Court of Appeals, Fourth Circuit.

Submitted: Jan. 13, 2009.

Decided: Jan. 15, 2009.

Orlando Wallace, Appellant Pro Se. Peter Sinclair Duffey, Assistant United States Attorney, Richmond, Virginia, for Appellee.

Before WILLIAMS, Chief Judge, and TRAXLER and KING, Circuit Judges.

PER CURIAM:

Orlando Wallace seeks to appeal the district court’s sealed order. In criminal cases, the defendant must file the notice of appeal within ten days after the entry of judgment. Fed. R.App. P. 4(b)(1)(A); *see United States v. Little,*392 F.3d 671, 680-81 (4th Cir.2004) (applying ten-day appeal period to appeal from Rule 35 ruling). With or without a motion, upon a showing of excusable neglect or good cause, the district court may grant an extension of up to thirty days to file a notice of appeal. Fed. R.App. P. 4(b)(4); *United States v. Reyes,*759 F.2d 351, 353 (4th Cir.1985).

The district court entered its order on February 29, 2008. The notice of appeal was filed on June 6, 2008.* Because Wal*823lace failed to file a timely notice of appeal or to obtain an extension of the appeal period, we dismiss the appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*DISMISSED.*

*

 For the purpose of this appeal, we assume that the date appearing on the notice of appeal is the earliest date it could have been properly delivered to prison officials for mailing to the court. Fed. R.App. P. 4(c); *Houston v. Lack,*487 U.S. 266, 108 S.Ct. 2379, 101 L.Ed.2d 245 (1988).
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          OCT-31-2000
<PERIOD-START>                             NOV-01-1999
<PERIOD-END>                               JUL-31-2000
<CASH>                                         130,043
<SECURITIES>                                         0
<RECEIVABLES>                                  200,361
<ALLOWANCES>                                    48,239
<INVENTORY>                                    107,078
<CURRENT-ASSETS>                               489,513
<PP&E>                                          24,206
<DEPRECIATION>                                 333,842
<TOTAL-ASSETS>                               4,461,572
<CURRENT-LIABILITIES>                        3,017,104
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        20,933
<OTHER-SE>                                   1,423,535
<TOTAL-LIABILITY-AND-EQUITY>                 4,461,572
<SALES>                                         21,569
<TOTAL-REVENUES>                                67,943
<CGS>                                          120,444
<TOTAL-COSTS>                                  680,267
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              (634,208)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (634,208)
<EPS-BASIC>                                      (.03)
<EPS-DILUTED>                                        0


</TABLE>
[Federal Register Volume 86, Number 139 (Friday, July 23, 2021)]
[Notices]
[Pages 39095-39096]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-15665]


=======================================================================
-----------------------------------------------------------------------

SMALL BUSINESS ADMINISTRATION

[License No. 09/49-0469]


Grayhawk Venture Fund II, L.P.; Surrender of License of Small 
Business Investment Company

    Pursuant to the authority granted to the United States Small 
Business Administration under the Small Business Investment Act of 
1958, as amended, under Section 309 of the Act and Section 107.1900 of 
the Small Business Administration Rules and Regulations (13 CFR 
107.1900) to function as a small business investment company under the 
Small Business Investment Company License No. 09/49-0469 issued to 
Grayhawk Venture

[[Page 39096]]

Fund II, L.P., said license is hereby declared null and void.

United States Small Business Administration.
Thomas G. Morris,
Acting Associate Administrator, Director, Office of SBIC Liquidation, 
Office of Investment and Innovation.
[FR Doc. 2021-15665 Filed 7-22-21; 8:45 am]
BILLING CODE P
# Official Journal C 2/2013

| | ISSN 1977-091X
  doi:10.3000/1977091X.C_2013.002.eng |
| --- | --- |
| Official Journal
  of the European Union | C 2 |
| | |
| English edition | Information and Notices | Volume 565 January 2013 |

ISSN 1977-091X

doi:10.3000/1977091X.C_2013.002.eng

Official Journal

of the European Union

C 2

English edition

Information and Notices

Volume 565 January 2013

---

| Notice No | Contents | page |
| --- | --- | --- |
| | II   Information |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2013/C 002/01 | Authorisation for State aid pursuant to Articles 107 and 108 of the TFEU — Cases where the Commission raises no objections (1) | 1 |

Notice No

Contents

page

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2013/C 002/01

Authorisation for State aid pursuant to Articles 107 and 108 of the TFEU — Cases where the Commission raises no objections (1)

1

---

| | IV   Notices |
| --- | --- |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2013/C 002/02 | Interest rate applied by the European Central Bank to its main refinancing operations: 0,75 % on 1 January 2013 — Euro exchange rates | 5 |

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2013/C 002/02

Interest rate applied by the European Central Bank to its main refinancing operations: 0,75 % on 1 January 2013 — Euro exchange rates

5

---

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN
#### Susan Murphy, Respondent, v State of New York, Appellant.

(Claim No. 115287.)

[945 NYS2d 918]

Appeal from an order of the Court of Claims (Diane L. Fitzpatrick, J.), entered March 15, 2011 in a personal injury action. The order sanctioned defendant for spoliation of evidence.

Now, upon reading and filing the stipulation withdrawing appeal signed by the attorneys for the parties on May 21, 2012,

It is hereby ordered that said appeal is unanimously dismissed without costs upon stipulation. Present — Scudder, P.J., Smith, Fahey, Lindley and Martoche, JJ.
_________________________________________ 

 

 

Order Michigan Supreme Court

Lansing, Michigan 

July 30, 2007 Clifford W. Taylor,

 Chief Justice 

133690 Michael F. Cavanagh 

Elizabeth A. Weaver 

Marilyn Kelly 

Maura D. Corrigan 

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff-Appellee, 

Robert P. Young, Jr. 

Stephen J. Markman,

 Justices 

v SC: 133690 

 COA: 275958 

Hillsdale CC: 05-290929-FH 

EUGENE ROY HILL,

Defendant-Appellant. 

_________________________________________/ 

On order of the Court, the application for leave to appeal the February 26, 2007 

order of the Court of Appeals is considered, and it is DENIED, because we are not 

persuaded that the questions presented should be reviewed by this Court. 

p0723 

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

July 30, 2007 

 Clerk
EXHIBIT
32




CERTIFICATIONS




Pursuant
to Section 906 of the Public Company Accounting Reform and Investor Protection
Act of 2002 (18 U.S.C. ss. 1350, as adopted), Jason Ash, Chief Executive Officer
and President of PacificHealth Laboratories, Inc. (the “Company”), and Stephen
P. Kuchen, Chief Financial Officer of the Company, each hereby certifies that,
to the best of his knowledge:




1.          The
Company’s Annual Report on Form 10-K/A for the period ended December 31, 2008,
and to which this Certification is attached as Exhibit 32 (the “Annual Report”)
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, as amended; and




2.          The
information contained in the Annual Report fairly presents, in all material
respects, the financial condition and results of operations of the Company at
the end of the period covered by the Annual Report.




A
signed original of this written statement required by Section 906 has been
provided to PacificHealth Laboratories, Inc. and will be retained by
PacificHealth Laboratories, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request.


DATE:
      March 16, 2009By:
                    /s/
      Jason AshJason
      Ash, Chief Executive Officer
                      (Principal
      Executive Officer)DATE:
      March 16, 2009By:
                    /s/
      Stephen P. KuchenStephen
      P. Kuchen, Chief Financial Officer
                      (Principal
      Financial and Accounting
Officer)
EXHIBIT
32.1





Certification
of Principal Executive Officer





CERTIFICATION
PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002


(18
U.S.C. SECTION 1350)





In
connection with the Quarterly Report of Metalline Mining Company (the “Company”)
on Form 10-Q for the quarter ended January 31, 2010 as filed with the Securities
and Exchange Commission on the date hereof (the “Report”), the undersigned
certifies pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to his knowledge:





(1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended; and





(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.





Dated:
      March 16, 2010
            By
            /s/ Merlin
      BinghamMerlin
      Bingham, Chief Executive Officer
# C_2019122EN.01002601.xml

| 1.4.2019 | EN | Official Journal of the European Union | C 122/26 |
| --- | --- | --- | --- |

1.4.2019

EN

Official Journal of the European Union

C 122/26

---

Action brought on 7 February 2019 — Pontinova v EUIPO — Ponti & Partners (pontinova)

(Case T-76/19)

(2019/C 122/29)

Language of the case: English

Parties

Applicant: Pontinova AG (Zürich, Switzerland) (represented by: K. Loth, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: Ponti & Partners, SLP (Barcelona, Spain)

Details of the proceedings before EUIPO

Applicant of the trade mark at issue: Applicant before the General Court

Trade mark at issue: Application for European Union figurative mark pontinova — Application for registration No 15 878 085

Procedure before EUIPO: Opposition proceedings

Contested decision: Decision of the Fifth Board of Appeal of EUIPO of 27 November 2018 in Case R 566/2018-5

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | award the costs in favour of the applicant. |
| --- | --- |

—

award the costs in favour of the applicant.

Plea in law

| — | Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council. |
| --- | --- |

—

Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.

---
III 

112TH CONGRESS 

1ST SESSION S. RES. 199 

Supporting the goals and ideals of ‘‘Crohn’s and Colitis Awareness Week’’. 

IN THE SENATE OF THE UNITED STATES 

MAY 25, 2011 

Mr. REID (for himself, Mr. REED, and Mr. COCHRAN) submitted the following 

resolution; which was referred to the Committee on Health, Education, 

Labor, and Pensions 

RESOLUTION 

Supporting the goals and ideals of ‘‘Crohn’s and Colitis 

Awareness Week’’. 

Whereas Crohn’s disease and ulcerative colitis are serious, 

chronic inflammatory diseases of the gastrointestinal 

tract; 

Whereas Crohn’s disease and ulcerative colitis, collectively 

known as inflammatory bowel disease, afflict approximately 1,400,000 people in the United States, 30 percent 

of whom are diagnosed as children; 

Whereas the cause of Crohn’s disease and ulcerative colitis 

are unknown and no medical cure exists; 

Whereas Crohn’s disease and ulcerative colitis can affect anyone, at any age, and is being diagnosed with increased 

frequency in children; 


tjames on DSKG8SOYB1PROD with BILLS
2 

•SRES 199 IS 

Whereas Crohn’s disease and ulcerative colitis patients are at 

high risk for developing colorectal cancer; 

Whereas a lack of awareness among health professionals and 

the general public may contribute to the misdiagnosis 

and mismanagement of Crohn’s disease and ulcerative colitis; 

Whereas the annual direct cost of Crohn’s disease and ulcerative colitis in the United States is estimated to be 

$6,100,000,000; 

Whereas the goals of ‘‘Crohn’s and Colitis Awareness Week’’ 

are— 

(1) to invite and encourage all people in the United 

States to join the effort to find a cure for Crohn’s disease 

and ulcerative colitis; 

(2) to engage in activities aimed at raising awareness of Crohn’s disease and ulcerative colitis among the 

general public and health care providers; and 

(3) to promote and support biomedical research 

needed to find better treatments and a cure for Crohn’s 

disease and ulcerative colitis; and 

Whereas the week of December 1, 2011, through December 

7, 2011, has been designated ‘‘Crohn’s and Colitis 

Awareness Week’’: Now, therefore, be it 

1 Resolved, That the Senate— 

2 (1) supports the goals and ideals of ‘‘Crohn’s 

3 and Colitis Awareness Week’’; 

4 (2) encourages media organizations to partici5 pate in ‘‘Crohn’s and Colitis Awareness Week’’ by 

6 helping to educate the general public about Crohn’s 

7 disease and ulcerative colitis; 


tjames on DSKG8SOYB1PROD with BILLS
3 

•SRES 199 IS 

1 (3) recognizes all people in the United States 

2 living with Crohn’s disease and ulcerative colitis and 

3 expresses appreciation to the family members and 

4 caregivers who support them; and 

5 (4) commends the dedication of health care pro6 fessionals and biomedical researchers who care for 

7 Crohn’s disease and ulcerative colitis patients and 

8 work to advance basic, genetic, and clinical research 

9 aimed at developing new treatments and a cure for 

10 Crohn’s disease and ulcerative colitis. 

Æ 


tjames on DSKG8SOYB1PROD with BILLS
Independent Accountants' Consent



The Board of Directors
Regent Assisted Living, Inc.:

We consent to incorporation by reference in the registration statements on Form
S-8 (Nos. 333-61239, 333-12159, and 333-12157) and Form S-3 (No. 333-55769) of
Regent Assisted Living, Inc. of our report dated February 13, 1998, relating to
the consolidated balance sheet of Regent Assisted Living, Inc. and subsidiaries
as of December 31, 1997, and the related consolidated statements of operations,
stockholders' equity, and cash flows for the year then ended, which report
appears in the December 31, 1998, annual report on Form 10-KSB of Regent
Assisted Living, Inc.


KPMG PEAT MARWICK LLP


Portland, Oregon
March 30, 1999
EXHIBIT 31.1



CERTIFICATION



I, Jack Gregory, certify that:



(1)    I have reviewed this quarterly report on Form 10-Q of Premier Holding Corp.;





(2)     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;





(3)     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;





(4)   The Registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant and have:





(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;





(c)     Evaluated the effectiveness of the Registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and





(d)     Disclosed in this report any change in the Registrants internal control over financial reporting that occurred during the Registrants most recent fiscal quarter (the Registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrants internal control over financial reporting; and





(5) The Registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrants auditors and the audit committee of the Registrants board of directors (or persons performing the equivalent functions):





(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrants ability to record, process, summarize and report financial information; and





(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrants internal control over financial reporting.



|Date: March 24, 2010 | Jack Gregory
Chief Executive Officer and Director
|-------------------- | -------------------------------------------------
#### William D. Teiner et al., Respondents, v Manooche Homayoon, M.D., P.C., et al., Defendants, and Dominic S. Garofalo, Appellant.

Order of the Supreme Court, New York County (S. Schwartz, J.), entered February 22, 1984, denying defendant-appellant’s motion to change the venue from New York County to Suffolk County, unanimously reversed, on the law and the facts and in the exercise of discretion, with costs, and the motion granted.

This is a medical malpractice action in New York County against several physicians, who maintain offices in Suffolk County, for personal injuries sustained as a result of their allegedly improper diagnosis of the plaintiff’s cardiac condition.

Defendant-appellant Garofalo sought a change in venue on the ground that all defendants reside in Suffolk, that the plaintiff is listed in the telephone directory in Suffolk and that the malpractice, if any, occurred in Suffolk.

The plaintiff is being treated at St. Vincent’s Hospital, in Manhattan, and alleges that he resides near there for treatment purposes and that he alternates visits between the two residences.

This action bears no relationship to New York County, other than a possible part-time residence for the plaintiff, and venue clearly belongs in Suffolk County. *(See, Rodziewicz v Dorfgood Realty Co.,*88 AD2d 565.) Concur — Kupferman, J. P., Ross, Asch and Fein. JJ.
**EXHIBIT 32.1**

 

**CERTIFICATIONS**

 

In connection with theQuarterly Report of StarTek, Inc. on Form 10-Q for the quarter ended March 31,2010, as filed with the Securities and Exchange Commission on the date hereof(the “Report”), each of the undersigned individuals, certifies, pursuant to 18U.S.C. Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, that to his knowledge:

 

1)              The Report fully complies with therequirements of Section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and

 

2)              The information contained in the Reportfairly presents, in all material respects, the financial condition and resultof operations of the Registrant.

 
| Date: May 7, 2010 | /s/A. LAURENCE JONES                                             |
|------------------------|------------------------------------------------------------------|
|                   | A. Laurence Jones                                                |
|                   | President and Chief  Executive Officer                           |
| * *               | * *                                                         |
|                   |                                                             |
| Date: May 7, 2010 | /s/ DAVID G. DURHAM                                              |
|                   | David G. Durham                                                  |
|                   | Executive Vice  President, Chief Financial Officer and Treasurer |

 

A signed original of thiswritten statement required by Section 906, or other documentauthenticating, acknowledging, or otherwise adopting the signature that appearsin typed form within the electronic version of this written statement requiredby Section 906, has been provided to the Corporation and will be retainedby the Corporation and furnished to the Securities and Exchange Commission orits staff upon request.

 

----